October 4, 2018
FDA: Endo Pharmaceuticals recalls two lots of Robaxin
Editor's Note
The Food & Drug Administration on September 28 announced the recall by Endo Pharmaceuticals Inc of two lots of Robaxin 750 mg tablets because of incorrect dosing information on the label.
Robaxin contains methocarbamol, which is used as a muscle relaxant. Patients who follow the incorrect dosing information may experience significant drowsiness and dizziness or they may have an overdose that results in seizures, coma, or death.
To date, the company has not received any reports of adverse events related to the recall.
Free Daily News
- Hospital safety grades show progress in reducing medical errors, infections
- Analysis: Overuse of back surgeries costs Medicare $2 billion, risks patient safety
- AI-powered surgical robot learns by watching
- AHA's Congressional "wish list" calls for financial relief, patient access, workforce protections
- Out-of-hospital cardiac arrest survival rates lag pre-pandemic levels, racial disparities persist
- Honoring the OR Manager Award winners this Perioperative Nurses Week
- Study: Demand for anesthesiologists rises sharply, driven by job market, regional variations
- Joint Commission Sentinel Event Alert details environmental disaster preparation
- ACS recognizes 77 hospitals for excellence in surgical outcomes
- Color-changing gel could enhance cataract surgery safety, efficiency
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement